NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program Published. Feb 21, 2025 8:00am EST.

The global frontotemporal dementia market is experiencing robust growth due to the increasing prevalence of neurodegenerative disorders, advancements in diagnostic and therapeutic technologies, and ...

Key protein changes could trigger frontotemporal dementia in middle age, a recent study has found. Image credit: Westend61/Getty Images. This article originally appeared on Medical News Today ...

Passage Bio reports positive Phase 1/2 trial results for PBFT02 in frontotemporal dementia, with planned protocol amendments for safety optimization. Passage Bio, Inc. announced positive results ...

Experts have highlighted an atypical symptom of dementia that appears as unusual food cravings, particularly observed in cases of frontotemporal dementia, as explained by the Alzheimer's Society ...

SANTA ANA, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and ...